nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefadroxil—SLC22A8—urine—urinary bladder cancer	0.0317	0.192	CbGeAlD
Cefadroxil—SLC15A1—epithelium—urinary bladder cancer	0.0116	0.0703	CbGeAlD
Cefadroxil—SLC22A8—prostate gland—urinary bladder cancer	0.0114	0.0689	CbGeAlD
Cefadroxil—SLC15A1—renal system—urinary bladder cancer	0.0108	0.0652	CbGeAlD
Cefadroxil—SLC15A2—prostate gland—urinary bladder cancer	0.0099	0.0598	CbGeAlD
Cefadroxil—SLC22A5—prostate gland—urinary bladder cancer	0.00861	0.052	CbGeAlD
Cefadroxil—SLC15A2—seminal vesicle—urinary bladder cancer	0.00837	0.0506	CbGeAlD
Cefadroxil—SLC15A1—vagina—urinary bladder cancer	0.00782	0.0473	CbGeAlD
Cefadroxil—SLC22A8—renal system—urinary bladder cancer	0.00776	0.0469	CbGeAlD
Cefadroxil—SLC22A5—seminal vesicle—urinary bladder cancer	0.00728	0.044	CbGeAlD
Cefadroxil—SLC15A2—renal system—urinary bladder cancer	0.00675	0.0408	CbGeAlD
Cefadroxil—SLC15A2—urethra—urinary bladder cancer	0.00663	0.0401	CbGeAlD
Cefadroxil—SLC22A5—renal system—urinary bladder cancer	0.00587	0.0355	CbGeAlD
Cefadroxil—SLC22A5—urethra—urinary bladder cancer	0.00577	0.0348	CbGeAlD
Cefadroxil—SLC15A2—female reproductive system—urinary bladder cancer	0.0054	0.0327	CbGeAlD
Cefadroxil—SLC15A2—vagina—urinary bladder cancer	0.00489	0.0295	CbGeAlD
Cefadroxil—SLC22A5—female reproductive system—urinary bladder cancer	0.0047	0.0284	CbGeAlD
Cefadroxil—Cefdinir—MPO—urinary bladder cancer	0.00436	0.502	CrCbGaD
Cefadroxil—Cefaclor—MPO—urinary bladder cancer	0.00432	0.498	CrCbGaD
Cefadroxil—SLC22A5—vagina—urinary bladder cancer	0.00425	0.0257	CbGeAlD
Cefadroxil—Diarrhoea—Mitomycin—urinary bladder cancer	0.00346	0.00419	CcSEcCtD
Cefadroxil—Cramp muscle—Etoposide—urinary bladder cancer	0.00335	0.00405	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.00335	0.00405	CcSEcCtD
Cefadroxil—Dizziness—Mitomycin—urinary bladder cancer	0.00334	0.00405	CcSEcCtD
Cefadroxil—Pancytopenia—Cisplatin—urinary bladder cancer	0.00333	0.00403	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00333	0.00403	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.00328	0.00397	CcSEcCtD
Cefadroxil—Vomiting—Mitomycin—urinary bladder cancer	0.00322	0.00389	CcSEcCtD
Cefadroxil—Rash—Mitomycin—urinary bladder cancer	0.00319	0.00386	CcSEcCtD
Cefadroxil—Dermatitis—Mitomycin—urinary bladder cancer	0.00319	0.00386	CcSEcCtD
Cefadroxil—Headache—Mitomycin—urinary bladder cancer	0.00317	0.00384	CcSEcCtD
Cefadroxil—SLC15A2—lymph node—urinary bladder cancer	0.00316	0.0191	CbGeAlD
Cefadroxil—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00313	0.00379	CcSEcCtD
Cefadroxil—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00308	0.00373	CcSEcCtD
Cefadroxil—Vaginal inflammation—Methotrexate—urinary bladder cancer	0.00307	0.00371	CcSEcCtD
Cefadroxil—Tension—Thiotepa—urinary bladder cancer	0.00306	0.0037	CcSEcCtD
Cefadroxil—Pancytopenia—Etoposide—urinary bladder cancer	0.00305	0.00369	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Epirubicin—urinary bladder cancer	0.00303	0.00367	CcSEcCtD
Cefadroxil—Nervousness—Thiotepa—urinary bladder cancer	0.00303	0.00366	CcSEcCtD
Cefadroxil—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00303	0.00366	CcSEcCtD
Cefadroxil—Creatinine increased—Epirubicin—urinary bladder cancer	0.00302	0.00365	CcSEcCtD
Cefadroxil—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00301	0.00365	CcSEcCtD
Cefadroxil—Neutropenia—Etoposide—urinary bladder cancer	0.003	0.00364	CcSEcCtD
Cefadroxil—Nausea—Mitomycin—urinary bladder cancer	0.003	0.00364	CcSEcCtD
Cefadroxil—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00298	0.0036	CcSEcCtD
Cefadroxil—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00296	0.00359	CcSEcCtD
Cefadroxil—Vaginal infection—Methotrexate—urinary bladder cancer	0.0029	0.00351	CcSEcCtD
Cefadroxil—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00288	0.00349	CcSEcCtD
Cefadroxil—Vaginal inflammation—Epirubicin—urinary bladder cancer	0.00287	0.00348	CcSEcCtD
Cefadroxil—Phosphatase alkaline increased—Epirubicin—urinary bladder cancer	0.00287	0.00348	CcSEcCtD
Cefadroxil—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00285	0.00345	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00284	0.00344	CcSEcCtD
Cefadroxil—Blood bilirubin increased—Doxorubicin—urinary bladder cancer	0.00281	0.0034	CcSEcCtD
Cefadroxil—Creatinine increased—Doxorubicin—urinary bladder cancer	0.00279	0.00338	CcSEcCtD
Cefadroxil—SLC22A5—lymph node—urinary bladder cancer	0.00275	0.0166	CbGeAlD
Cefadroxil—Vaginal infection—Epirubicin—urinary bladder cancer	0.00271	0.00328	CcSEcCtD
Cefadroxil—Blood urea increased—Epirubicin—urinary bladder cancer	0.00271	0.00328	CcSEcCtD
Cefadroxil—Convulsion—Thiotepa—urinary bladder cancer	0.0027	0.00327	CcSEcCtD
Cefadroxil—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.00269	0.00326	CcSEcCtD
Cefadroxil—Agranulocytosis—Etoposide—urinary bladder cancer	0.00267	0.00324	CcSEcCtD
Cefadroxil—Phosphatase alkaline increased—Doxorubicin—urinary bladder cancer	0.00266	0.00322	CcSEcCtD
Cefadroxil—Vaginal inflammation—Doxorubicin—urinary bladder cancer	0.00266	0.00322	CcSEcCtD
Cefadroxil—Arthralgia—Thiotepa—urinary bladder cancer	0.00265	0.00321	CcSEcCtD
Cefadroxil—Vaginal infection—Doxorubicin—urinary bladder cancer	0.00251	0.00304	CcSEcCtD
Cefadroxil—Blood urea increased—Doxorubicin—urinary bladder cancer	0.00251	0.00304	CcSEcCtD
Cefadroxil—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00249	0.00302	CcSEcCtD
Cefadroxil—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00249	0.00302	CcSEcCtD
Cefadroxil—Hepatic failure—Methotrexate—urinary bladder cancer	0.00248	0.003	CcSEcCtD
Cefadroxil—Erythema multiforme—Etoposide—urinary bladder cancer	0.00243	0.00294	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.0024	0.0029	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00238	0.00289	CcSEcCtD
Cefadroxil—Muscle spasms—Cisplatin—urinary bladder cancer	0.00235	0.00284	CcSEcCtD
Cefadroxil—Hepatic failure—Epirubicin—urinary bladder cancer	0.00232	0.00281	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00232	0.00281	CcSEcCtD
Cefadroxil—Somnolence—Thiotepa—urinary bladder cancer	0.00226	0.00274	CcSEcCtD
Cefadroxil—Dyspepsia—Thiotepa—urinary bladder cancer	0.00224	0.00271	CcSEcCtD
Cefadroxil—Convulsion—Fluorouracil—urinary bladder cancer	0.00223	0.0027	CcSEcCtD
Cefadroxil—Arthralgia—Gemcitabine—urinary bladder cancer	0.00223	0.0027	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.00222	0.00268	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00221	0.00267	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.0022	0.00266	CcSEcCtD
Cefadroxil—Muscle spasms—Etoposide—urinary bladder cancer	0.00215	0.00261	CcSEcCtD
Cefadroxil—Hepatic failure—Doxorubicin—urinary bladder cancer	0.00215	0.0026	CcSEcCtD
Cefadroxil—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00214	0.00259	CcSEcCtD
Cefadroxil—Convulsion—Cisplatin—urinary bladder cancer	0.00212	0.00256	CcSEcCtD
Cefadroxil—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.0021	0.00255	CcSEcCtD
Cefadroxil—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00209	0.00254	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00208	0.00252	CcSEcCtD
Cefadroxil—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00206	0.00249	CcSEcCtD
Cefadroxil—Urticaria—Thiotepa—urinary bladder cancer	0.00202	0.00245	CcSEcCtD
Cefadroxil—Vertigo—Etoposide—urinary bladder cancer	0.00201	0.00244	CcSEcCtD
Cefadroxil—Abdominal pain—Thiotepa—urinary bladder cancer	0.00201	0.00243	CcSEcCtD
Cefadroxil—Body temperature increased—Thiotepa—urinary bladder cancer	0.00201	0.00243	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.002	0.00243	CcSEcCtD
Cefadroxil—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00199	0.00241	CcSEcCtD
Cefadroxil—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00195	0.00236	CcSEcCtD
Cefadroxil—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.00195	0.00236	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00195	0.00236	CcSEcCtD
Cefadroxil—Convulsion—Etoposide—urinary bladder cancer	0.00194	0.00235	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00192	0.00232	CcSEcCtD
Cefadroxil—Eosinophilia—Methotrexate—urinary bladder cancer	0.00191	0.00231	CcSEcCtD
Cefadroxil—Somnolence—Gemcitabine—urinary bladder cancer	0.0019	0.0023	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00188	0.00227	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00188	0.00227	CcSEcCtD
Cefadroxil—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00187	0.00227	CcSEcCtD
Cefadroxil—Somnolence—Fluorouracil—urinary bladder cancer	0.00187	0.00226	CcSEcCtD
Cefadroxil—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00185	0.00224	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00185	0.00224	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00184	0.00223	CcSEcCtD
Cefadroxil—Pancytopenia—Methotrexate—urinary bladder cancer	0.00183	0.00221	CcSEcCtD
Cefadroxil—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00183	0.00221	CcSEcCtD
Cefadroxil—Asthenia—Thiotepa—urinary bladder cancer	0.00182	0.00221	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00182	0.0022	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00182	0.0022	CcSEcCtD
Cefadroxil—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.00181	0.00219	CcSEcCtD
Cefadroxil—Neutropenia—Methotrexate—urinary bladder cancer	0.0018	0.00218	CcSEcCtD
Cefadroxil—Pruritus—Thiotepa—urinary bladder cancer	0.0018	0.00218	CcSEcCtD
Cefadroxil—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00179	0.00217	CcSEcCtD
Cefadroxil—Eosinophilia—Epirubicin—urinary bladder cancer	0.00178	0.00216	CcSEcCtD
Cefadroxil—Diarrhoea—Thiotepa—urinary bladder cancer	0.00174	0.00211	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00174	0.0021	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00174	0.0021	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00172	0.00208	CcSEcCtD
Cefadroxil—Drowsiness—Methotrexate—urinary bladder cancer	0.00172	0.00208	CcSEcCtD
Cefadroxil—Pancytopenia—Epirubicin—urinary bladder cancer	0.00171	0.00207	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.0017	0.00206	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.0017	0.00206	CcSEcCtD
Cefadroxil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00169	0.00205	CcSEcCtD
Cefadroxil—Neutropenia—Epirubicin—urinary bladder cancer	0.00168	0.00204	CcSEcCtD
Cefadroxil—Dizziness—Thiotepa—urinary bladder cancer	0.00168	0.00204	CcSEcCtD
Cefadroxil—Urticaria—Fluorouracil—urinary bladder cancer	0.00167	0.00202	CcSEcCtD
Cefadroxil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00166	0.00201	CcSEcCtD
Cefadroxil—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00165	0.002	CcSEcCtD
Cefadroxil—Somnolence—Etoposide—urinary bladder cancer	0.00162	0.00197	CcSEcCtD
Cefadroxil—Vomiting—Thiotepa—urinary bladder cancer	0.00162	0.00196	CcSEcCtD
Cefadroxil—Drowsiness—Epirubicin—urinary bladder cancer	0.00161	0.00194	CcSEcCtD
Cefadroxil—Rash—Thiotepa—urinary bladder cancer	0.0016	0.00194	CcSEcCtD
Cefadroxil—Dermatitis—Thiotepa—urinary bladder cancer	0.0016	0.00194	CcSEcCtD
Cefadroxil—Agranulocytosis—Methotrexate—urinary bladder cancer	0.0016	0.00194	CcSEcCtD
Cefadroxil—Headache—Thiotepa—urinary bladder cancer	0.00159	0.00193	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00159	0.00193	CcSEcCtD
Cefadroxil—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00158	0.00192	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00158	0.00191	CcSEcCtD
Cefadroxil—Body temperature increased—Cisplatin—urinary bladder cancer	0.00158	0.00191	CcSEcCtD
Cefadroxil—Neutropenia—Doxorubicin—urinary bladder cancer	0.00156	0.00189	CcSEcCtD
Cefadroxil—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00155	0.00188	CcSEcCtD
Cefadroxil—Haemoglobin—Methotrexate—urinary bladder cancer	0.00155	0.00187	CcSEcCtD
Cefadroxil—Haemorrhage—Methotrexate—urinary bladder cancer	0.00154	0.00187	CcSEcCtD
Cefadroxil—Asthenia—Gemcitabine—urinary bladder cancer	0.00154	0.00186	CcSEcCtD
Cefadroxil—Pruritus—Gemcitabine—urinary bladder cancer	0.00151	0.00183	CcSEcCtD
Cefadroxil—Nausea—Thiotepa—urinary bladder cancer	0.00151	0.00183	CcSEcCtD
Cefadroxil—Agranulocytosis—Epirubicin—urinary bladder cancer	0.0015	0.00181	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00149	0.00181	CcSEcCtD
Cefadroxil—Pruritus—Fluorouracil—urinary bladder cancer	0.00149	0.0018	CcSEcCtD
Cefadroxil—Drowsiness—Doxorubicin—urinary bladder cancer	0.00149	0.0018	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00147	0.00178	CcSEcCtD
Cefadroxil—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00147	0.00178	CcSEcCtD
Cefadroxil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00146	0.00177	CcSEcCtD
Cefadroxil—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00146	0.00176	CcSEcCtD
Cefadroxil—Urticaria—Etoposide—urinary bladder cancer	0.00145	0.00176	CcSEcCtD
Cefadroxil—Haemoglobin—Epirubicin—urinary bladder cancer	0.00145	0.00175	CcSEcCtD
Cefadroxil—Body temperature increased—Etoposide—urinary bladder cancer	0.00144	0.00175	CcSEcCtD
Cefadroxil—Abdominal pain—Etoposide—urinary bladder cancer	0.00144	0.00175	CcSEcCtD
Cefadroxil—Haemorrhage—Epirubicin—urinary bladder cancer	0.00144	0.00175	CcSEcCtD
Cefadroxil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00144	0.00174	CcSEcCtD
Cefadroxil—Asthenia—Cisplatin—urinary bladder cancer	0.00143	0.00173	CcSEcCtD
Cefadroxil—Dizziness—Fluorouracil—urinary bladder cancer	0.00139	0.00168	CcSEcCtD
Cefadroxil—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00139	0.00168	CcSEcCtD
Cefadroxil—Diarrhoea—Cisplatin—urinary bladder cancer	0.00136	0.00165	CcSEcCtD
Cefadroxil—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00136	0.00165	CcSEcCtD
Cefadroxil—Vomiting—Gemcitabine—urinary bladder cancer	0.00136	0.00165	CcSEcCtD
Cefadroxil—Rash—Gemcitabine—urinary bladder cancer	0.00135	0.00163	CcSEcCtD
Cefadroxil—Dermatitis—Gemcitabine—urinary bladder cancer	0.00135	0.00163	CcSEcCtD
Cefadroxil—Hypersensitivity—Etoposide—urinary bladder cancer	0.00135	0.00163	CcSEcCtD
Cefadroxil—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00134	0.00162	CcSEcCtD
Cefadroxil—Headache—Gemcitabine—urinary bladder cancer	0.00134	0.00162	CcSEcCtD
Cefadroxil—Vomiting—Fluorouracil—urinary bladder cancer	0.00134	0.00162	CcSEcCtD
Cefadroxil—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00133	0.00161	CcSEcCtD
Cefadroxil—Rash—Fluorouracil—urinary bladder cancer	0.00133	0.00161	CcSEcCtD
Cefadroxil—Dermatitis—Fluorouracil—urinary bladder cancer	0.00133	0.0016	CcSEcCtD
Cefadroxil—Headache—Fluorouracil—urinary bladder cancer	0.00132	0.0016	CcSEcCtD
Cefadroxil—Asthenia—Etoposide—urinary bladder cancer	0.00131	0.00159	CcSEcCtD
Cefadroxil—Pruritus—Etoposide—urinary bladder cancer	0.00129	0.00157	CcSEcCtD
Cefadroxil—Nausea—Gemcitabine—urinary bladder cancer	0.00127	0.00154	CcSEcCtD
Cefadroxil—Vomiting—Cisplatin—urinary bladder cancer	0.00127	0.00154	CcSEcCtD
Cefadroxil—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00126	0.00153	CcSEcCtD
Cefadroxil—Rash—Cisplatin—urinary bladder cancer	0.00126	0.00152	CcSEcCtD
Cefadroxil—Dermatitis—Cisplatin—urinary bladder cancer	0.00126	0.00152	CcSEcCtD
Cefadroxil—Diarrhoea—Etoposide—urinary bladder cancer	0.00125	0.00151	CcSEcCtD
Cefadroxil—Nausea—Fluorouracil—urinary bladder cancer	0.00125	0.00151	CcSEcCtD
Cefadroxil—Tension—Epirubicin—urinary bladder cancer	0.00123	0.00149	CcSEcCtD
Cefadroxil—Nervousness—Epirubicin—urinary bladder cancer	0.00122	0.00148	CcSEcCtD
Cefadroxil—Dizziness—Etoposide—urinary bladder cancer	0.00121	0.00146	CcSEcCtD
Cefadroxil—Muscle spasms—Epirubicin—urinary bladder cancer	0.00121	0.00146	CcSEcCtD
Cefadroxil—Vertigo—Methotrexate—urinary bladder cancer	0.0012	0.00146	CcSEcCtD
Cefadroxil—Nausea—Cisplatin—urinary bladder cancer	0.00118	0.00143	CcSEcCtD
Cefadroxil—Convulsion—Methotrexate—urinary bladder cancer	0.00116	0.00141	CcSEcCtD
Cefadroxil—Vomiting—Etoposide—urinary bladder cancer	0.00116	0.00141	CcSEcCtD
Cefadroxil—Rash—Etoposide—urinary bladder cancer	0.00115	0.00139	CcSEcCtD
Cefadroxil—Dermatitis—Etoposide—urinary bladder cancer	0.00115	0.00139	CcSEcCtD
Cefadroxil—Headache—Etoposide—urinary bladder cancer	0.00114	0.00139	CcSEcCtD
Cefadroxil—Arthralgia—Methotrexate—urinary bladder cancer	0.00114	0.00138	CcSEcCtD
Cefadroxil—Tension—Doxorubicin—urinary bladder cancer	0.00114	0.00138	CcSEcCtD
Cefadroxil—Nervousness—Doxorubicin—urinary bladder cancer	0.00113	0.00137	CcSEcCtD
Cefadroxil—Vertigo—Epirubicin—urinary bladder cancer	0.00113	0.00137	CcSEcCtD
Cefadroxil—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00112	0.00135	CcSEcCtD
Cefadroxil—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00109	0.00133	CcSEcCtD
Cefadroxil—Convulsion—Epirubicin—urinary bladder cancer	0.00109	0.00132	CcSEcCtD
Cefadroxil—Nausea—Etoposide—urinary bladder cancer	0.00109	0.00131	CcSEcCtD
Cefadroxil—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00107	0.0013	CcSEcCtD
Cefadroxil—Arthralgia—Epirubicin—urinary bladder cancer	0.00107	0.00129	CcSEcCtD
Cefadroxil—Vertigo—Doxorubicin—urinary bladder cancer	0.00104	0.00126	CcSEcCtD
Cefadroxil—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00102	0.00124	CcSEcCtD
Cefadroxil—Convulsion—Doxorubicin—urinary bladder cancer	0.00101	0.00122	CcSEcCtD
Cefadroxil—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.001	0.00121	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000997	0.00121	CcSEcCtD
Cefadroxil—Arthralgia—Doxorubicin—urinary bladder cancer	0.000988	0.0012	CcSEcCtD
Cefadroxil—Somnolence—Methotrexate—urinary bladder cancer	0.000973	0.00118	CcSEcCtD
Cefadroxil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000963	0.00117	CcSEcCtD
Cefadroxil—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000948	0.00115	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000945	0.00114	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000933	0.00113	CcSEcCtD
Cefadroxil—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000928	0.00112	CcSEcCtD
Cefadroxil—Somnolence—Epirubicin—urinary bladder cancer	0.00091	0.0011	CcSEcCtD
Cefadroxil—Dyspepsia—Epirubicin—urinary bladder cancer	0.000901	0.00109	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000895	0.00108	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000884	0.00107	CcSEcCtD
Cefadroxil—Urticaria—Methotrexate—urinary bladder cancer	0.000869	0.00105	CcSEcCtD
Cefadroxil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000865	0.00105	CcSEcCtD
Cefadroxil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000865	0.00105	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000863	0.00105	CcSEcCtD
Cefadroxil—Somnolence—Doxorubicin—urinary bladder cancer	0.000842	0.00102	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000837	0.00101	CcSEcCtD
Cefadroxil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000834	0.00101	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000818	0.000991	CcSEcCtD
Cefadroxil—Urticaria—Epirubicin—urinary bladder cancer	0.000814	0.000985	CcSEcCtD
Cefadroxil—Body temperature increased—Epirubicin—urinary bladder cancer	0.00081	0.00098	CcSEcCtD
Cefadroxil—Abdominal pain—Epirubicin—urinary bladder cancer	0.00081	0.00098	CcSEcCtD
Cefadroxil—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000806	0.000976	CcSEcCtD
Cefadroxil—Asthenia—Methotrexate—urinary bladder cancer	0.000785	0.000951	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000775	0.000938	CcSEcCtD
Cefadroxil—Pruritus—Methotrexate—urinary bladder cancer	0.000774	0.000937	CcSEcCtD
Cefadroxil—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000755	0.000914	CcSEcCtD
Cefadroxil—Urticaria—Doxorubicin—urinary bladder cancer	0.000753	0.000911	CcSEcCtD
Cefadroxil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000749	0.000907	CcSEcCtD
Cefadroxil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000749	0.000907	CcSEcCtD
Cefadroxil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000749	0.000907	CcSEcCtD
Cefadroxil—Asthenia—Epirubicin—urinary bladder cancer	0.000735	0.00089	CcSEcCtD
Cefadroxil—Pruritus—Epirubicin—urinary bladder cancer	0.000725	0.000877	CcSEcCtD
Cefadroxil—Dizziness—Methotrexate—urinary bladder cancer	0.000724	0.000876	CcSEcCtD
Cefadroxil—Diarrhoea—Epirubicin—urinary bladder cancer	0.000701	0.000848	CcSEcCtD
Cefadroxil—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000698	0.000845	CcSEcCtD
Cefadroxil—Vomiting—Methotrexate—urinary bladder cancer	0.000696	0.000842	CcSEcCtD
Cefadroxil—Rash—Methotrexate—urinary bladder cancer	0.00069	0.000835	CcSEcCtD
Cefadroxil—Dermatitis—Methotrexate—urinary bladder cancer	0.000689	0.000835	CcSEcCtD
Cefadroxil—Headache—Methotrexate—urinary bladder cancer	0.000686	0.00083	CcSEcCtD
Cefadroxil—Asthenia—Doxorubicin—urinary bladder cancer	0.00068	0.000823	CcSEcCtD
Cefadroxil—Dizziness—Epirubicin—urinary bladder cancer	0.000677	0.00082	CcSEcCtD
Cefadroxil—Pruritus—Doxorubicin—urinary bladder cancer	0.00067	0.000812	CcSEcCtD
Cefadroxil—Vomiting—Epirubicin—urinary bladder cancer	0.000651	0.000788	CcSEcCtD
Cefadroxil—Nausea—Methotrexate—urinary bladder cancer	0.00065	0.000787	CcSEcCtD
Cefadroxil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000648	0.000785	CcSEcCtD
Cefadroxil—Rash—Epirubicin—urinary bladder cancer	0.000646	0.000782	CcSEcCtD
Cefadroxil—Dermatitis—Epirubicin—urinary bladder cancer	0.000645	0.000781	CcSEcCtD
Cefadroxil—Headache—Epirubicin—urinary bladder cancer	0.000642	0.000777	CcSEcCtD
Cefadroxil—Dizziness—Doxorubicin—urinary bladder cancer	0.000627	0.000759	CcSEcCtD
Cefadroxil—Nausea—Epirubicin—urinary bladder cancer	0.000608	0.000737	CcSEcCtD
Cefadroxil—Vomiting—Doxorubicin—urinary bladder cancer	0.000602	0.00073	CcSEcCtD
Cefadroxil—Rash—Doxorubicin—urinary bladder cancer	0.000597	0.000723	CcSEcCtD
Cefadroxil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000597	0.000723	CcSEcCtD
Cefadroxil—Headache—Doxorubicin—urinary bladder cancer	0.000594	0.000719	CcSEcCtD
Cefadroxil—Nausea—Doxorubicin—urinary bladder cancer	0.000563	0.000682	CcSEcCtD
